MODERNA, MERCK REPORT POSITIVE RESULTS FROM CANCER-VACCINE STUDY

Summary from the TLDR newsletter

In a Phase 2b trial, Moderna and Merck's cancer vaccine reduced the risk of relapse or death in melanoma patients by 49% when used in combination with Merck's immunotherapy Keytruda, compared to when using Keytruda alone. The results illustrate mRNA's potential in cancer care. The treatment continues to demonstrate sustained and clinically meaningful improvement. The companies are currently running eight Phase 2 and Phase 3 clinical trials across multiple tumor types.